Liquidia Corporation
LQDA
Kedudukan dalam Saham
#4457
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Harga Saham
$38.75
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$3.47B
Perubahan (1 hari)
6.60%
Perubahan (1 tahun)
73.46%
Negara
US
Perdagangan Liquidia Corporation (LQDA)
Kategori
Healthcare
Sejarah harga saham bagi Liquidia Corporation (LQDA)
Harga penutupan tertinggi: $30.60 pada 2026-10-01
Harga penutupan terendah: $11.01 pada 2018-07-01
Harga penutupan terendah: $11.01 pada 2018-07-01
Sejarah harga saham Liquidia Corporation dari 2018 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 42.98% |
| 2025 | 204.28% |
| 2024 | 26.82% |
| 2023 | 47.93% |
| 2022 | 37.03% |
| 2021 | 48.32% |
| 2020 | -24.23% |
| 2019 | -82.68% |
| 2018 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $46.29 | 37.83% |
SE
|
|
| $171.04 | 23.67% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
